Prediction of abacavir resistance from genotypic data: Impact of zidovudine and lamivudine resistance in vitro and in vivo

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 1, 2002, Pages 89-94

  Walter, H ^a   Schmidt, B ^a   Werwein, M ^a   Schwingel, E ^a   Korn, K ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ARGININE; ASPARTIC ACID; GLUTAMIC ACID; ISOLEUCINE; LAMIVUDINE; LEUCINE; LYSINE; METHIONINE; PHENYLALANINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TYROSINE; VALINE; ZIDOVUDINE;

ACCURACY; ARTICLE; CODON; CONTROLLED STUDY; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RETROVIRUS; SCORING SYSTEM; SITE DIRECTED MUTAGENESIS; TREATMENT PLANNING; VIRAL GENETICS; VIRUS RESISTANCE;

ALGORITHMS; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MICROBIAL; GENE FREQUENCY; GENOTYPE; HIV; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; ZIDOVUDINE;

EID: 0036135318     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.1.89-94.2002     Document Type: Article

References (25)

1. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity
2. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
3. Epidemiology and conditions of selection of 44D/A and/or 118I reverse transcriptase mutations in 344 patients
4. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction
5. Abacavir
6. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy
7. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
8. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
9. Abacavir. A review of its clinical potential in patients with HIV infection
10. Site directed mutagenesis by overlap extension using the polymerase chain reaction
11. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: Results from a randomized, double-blind trial
12. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine
13. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort study
14. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleotide analog resistance
15. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus
16. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates
17. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy
18. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
19. Mutations in retroviral genes associated with drug resistance: 2000-2001 Update
20. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance
21. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries
22. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects
23. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
24. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir
25. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors